



**Comment on "Clinical Significance of the Water Retention and Barrier Function-Improving Capabilities of Ceramide-Containing Formulations: A Qualitative Review"**

Journal:	<i>The Journal of Dermatology</i>
Manuscript ID	JDE-2021-1536.R1
Wiley - Manuscript type:	Letter to the Editor
Date Submitted by the Author:	n/a
Complete List of Authors:	Rawlings, Anthony; University College London, School of Pharmacy Lane, Majella; University College London, School of Pharmacy
Keywords:	ceramide, water retention, skin barrier, formulation, classification
Abstract:	

SCHOLARONE™  
Manuscripts

1  
2  
3 **Comment on "Clinical Significance of the Water Retention and Barrier Function-**  
4  
5 **Improving Capabilities of Ceramide-Containing Formulations: A Qualitative Review"**  
6  
7

8 Anthony V. Rawlings<sup>1,2</sup> & Majella E. Lane<sup>2</sup>.  
9

10  
11 <sup>1</sup>AVR Consulting Ltd., Northwich, Cheshire, UK.  
12

13  
14 <sup>2</sup>Department of Pharmaceutics, University College London School of Pharmacy, 29-39  
15 Brunswick Square, London WC1N 1AX, UK.  
16  
17

18  
19 **Author contact details:**  
20

21  
22 Majella. E. Lane.  
23

24  
25 Email: m.lane@ucl.ac.uk;  
26

27  
28 Telephone: +447445979877  
29

30  
31 **Running title:** Letter to editor  
32

33  
34 **Keywords:** Skin barrier, Stratum corneum, Ceramide, Moisturization, Dry skin.  
35

36  
37 **Corresponding author:** Dr Majella. E. Lane  
38

39  
40 Department of Pharmaceutics, University College London School of Pharmacy,  
41  
42 29-39 Brunswick Square, London WC1N 1AX, UK.  
43  
44

45  
46  
47  
48  
49 Tel: +447445979877; Email: m.lane@ucl.ac.uk.  
50  
51

52  
53  
54  
55  
56  
57  
58 Dear Editor,  
59  
60

1  
2  
3 We support the analysis of Kono *et al.* the publication of '*Clinical significance of the water*  
4 *retention and barrier function-improving capabilities of ceramide-containing formulations*'  
5  
6 recently published in the Journal of Dermatology [1]. ~~Kono *et al.*~~ We especially applaud the  
7  
8 authors on their conclusion for the need to determine the efficacy of different ceramides used  
9  
10 in dermatological products and also for greater clarity of the particular ceramides used. Here  
11  
12 we are not addressing efficacy but the importance of declaring the precise molecular structures  
13  
14 of the ceramides used. In our opinions there is confusion in the literature of the definition of  
15  
16 ceramides versus other molecules (pseudoceramides) that mimic some of their physiochemical  
17  
18 and biological behaviour with the result that some formulations containing so called  
19  
20 physiological lipids actually contain molecules that are not skin-identical ceramides. Moreover,  
21  
22 usually the concentrations of ceramides used in products is not always disclosed.  
23  
24  
25  
26  
27  
28

29 The generalised structures of ceramides used in skin care products are shown in Figure 1A.  
30  
31 Many studies have been conducted using these ceramides but not all publications use the  
32  
33 correct International Nomenclature of Cosmetic Ingredients (INCI) nomenclature [42]. It is  
34  
35 important to correctly classify these lipids as they possess different physical characteristics  
36  
37 especially the acylceramides CER EOS & EOP [23]. Moreover, we have called for even greater  
38  
39 clarity on the types of omega-esterified fatty acids within these molecules as these also dictate  
40  
41 their behaviour [42, 34]. It is also important to note that in some cases racemic rather than  
42  
43 stereospecific ceramides are used in skin care products. The effects of using the stereospecific  
44  
45 and nature-identical sphingoid bases (2S, 3R-sphingosine and 2S, 3S, 4R-phytosphingosine  
46  
47 etc.) together with R- $\alpha$ -hydroxy fatty acids have recently been studied [45,56]. For at least one  
48  
49 marketed Ceramide AP the  $\alpha$ -hydroxy fatty acid component consists of the two diastereomers  
50  
51 of which the natural R-isomer promotes tighter lipid packing and the authors conclude that it  
52  
53 should be preferred compared with the unnatural S-isomer or the racemic version [56].  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The representative structures of other types of molecules (pseudoceramides) that are used in  
4 skin care products are shown in Figure 1B. Moreover, in comparison to skin ceramides none  
5  
6 of these contain intricate esters of long chain omega-hydroxy fatty acids like those in  
7  
8 acylceramides or N-acylated  $\alpha$ -hydroxy fatty acids or multiple sphingoid-like base mimics.  
9  
10 Only one contains multiple chain length species but it is still not as complex as the ceramides  
11  
12 found in skin [Figure 1B (vii)] and none possess the heterogenous diversity of the natural  
13  
14 molecular species. Although these retain some, but not all, of the characteristics of skin-  
15  
16 identical ceramides their correct chemical classification needs to be recorded and labelled as  
17  
18 pseudoceramides or as ceramide-mimics rather than ceramides in ceramide-  
19  
20 dominant/pseudoceramide-dominant formulations.  
21  
22  
23  
24  
25

26  
27 In conclusion, in order to compare efficacy of ceramides there needs to be greater scientific  
28  
29 clarity of the chemistry of ceramides and/or ceramide mimics used together with precise  
30  
31 concentrations. The INCI nomenclature is insufficient for scientific scrutiny of the data and  
32  
33 precise molecular and stereochemical details of the ceramides/pseudoceramides used should  
34  
35 be reported.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References.**

1. T. Kono, Y. Miyachi, M. Kawashima. Clinical significance of the water retention and barrier function-improving capabilities of ceramide-containing formulations. *J. Dermatol.* 2021; doi: 10.1111/1346-8138.16175.
2. Rawlings AV, Lane ME. Letter to the Editor Regarding 'An Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1'. *Dermatol Ther (Heidelb)*. 2021 (In press).
3. Opalka L, Kovacik A, Pullmannova P, Maixner J, Vavrova K. Effects of omega-O-acylceramide structures and concentrations in healthy and diseased skin barrier lipid membrane models. *J Lipid Res*. 2020;61(2):219-28.
4. de Sousa Neto D, Gooris G, Bouwstra J. Effect of the omega-acylceramides on the lipid organization of stratum corneum model membranes evaluated by X-ray diffraction and FTIR studies (Part I). *Chem Phys Lipids*. 2011;164(3):184-95.
5. Kovacik A, Pullmannova P, Opalka L, Silarova M, Maixner J, Vavrova K. Effects of (R)- and (S)-alpha-Hydroxylation of Acyl Chains in Sphingosine, Dihydrosphingosine, and Phytosphingosine Ceramides on Phase Behavior and Permeability of Skin Lipid Models. *Int J Mol Sci*. 2021;22(14).

1  
2  
3 6. Strati F, Oliveira JSL, Opalka L, Mukhina T, Dobner B, Neubert RHH, et al. Two- and  
4  
5 Three-Dimensional Physical-Chemical Characterization of CER[AP]: A Study of  
6  
7 Stereochemistry and Chain Symmetry. J Phys Chem B. 2021;125(35):9960-9.  
8  
9  
10  
11  
12  
13  
14  
15  
16

17  
18 **Legend.**

19 Figure 1. A Representation of the most common ceramides used in skin care products.  
20  
21 Ceramide EOS (R=linoleate, oleate stearate etc.) (i), EOP (ii), NS (iii), NP (iv), AP (v). B.  
22  
23 Representation of the most common pseudoceramides used in skin care products.  
24  
25 Pseudoceramide: Cetyl-PG hydroxyethyl palmitamide (Sphingolipid E, SLC66) (vi).  
26  
27 Pseudoceramide: myristyl/palmityl-oxo-stearamide/ arachimide MEA is a mixture of myristyl-  
28  
29 oxostearamide MEA, palmityl-oxostearamide MEA, myristyl-oxoarachamide and palmityl-  
30  
31 oxoarachamide MEA. (vii). N-palmitoyl-4-hydroxy-L-Proline Palmitoyl Ester (Bio391) (viii).  
32  
33 Pseudoceramide PC-104, 1,3-bis(N-2-(hydroxyethyl)palmitoylamino)-2-hydroxypropane (ix).  
34  
35  
36  
37

38 **Acknowledgments:**

39  
40  
41 *Compliance with Ethics Guidelines:* This article is based on previously conducted studies and  
42  
43 does not contain any new studies with human participants or animals performed by any of the  
44  
45 authors.  
46  
47

48  
49 *Funding:* No funding or sponsorship was received for this study or publication of this article.  
50  
51

52 *Authorship:* All named authors meet the International Committee of Medical Journal Editors  
53  
54 (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work  
55  
56 as a whole, and have given their approval for this version to be published.  
57  
58  
59  
60


1  
2  
3 *Data availability:* Data sharing is not applicable to this article as no datasets were generated or  
4 analyzed during the current study.  
5  
6  
7

8 *Disclosures:* Anthony V Rawlings currently consults for No 7 Beauty Company (Member of  
9 Walgreens Boots Alliance), DSM Nutritional Products Limited, GlaxoSmithKline Consumer  
10 Healthcare Limited and Union Swiss. Majella E. Lane has nothing to disclose.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


For Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

Figure 1: Common ceramides found in skincare products




(i) Ceramide EOS




(ii) Ceramide EOP


R= Linoleate, Oleate, Stearate etc.



(iii) Ceramide NS



(iv) Ceramide NP




(v) Ceramide AP




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41


Figure 1: Common pseudoceramides found in skincare products




(vi) Sphingolipid E (SLC66)  
(Cetyl-PG Hydroxyethyl  
Palmitamide)



(viii) N-palmitoyl-4-hydroxy-L-Proline Palmitoyl



(vii) Myristyl/palmityl-oxo-stearamide/arachimide MEA



(ix) 1,3-bis(N-2-(hydroxyethyl)palmitoylamino)-2-hydroxypropane  
(Ceramide PC104)